Surgical Science Q4 2022: The growth story continues - Redeye

Redeye updates its estimates following Surgical Science’s Q4 2022 report, which broadly aligned with our expectations. Margins were slightly softer than we had pencilled in, but we judge that Surgical Science’s long-term prospects remain unchanged. We make minor changes to our estimates and valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/883943/surgical-science-q4-2022-the-growth-story-continues?utm_source=finwire&utm_medium=RSS